Epistem assists in combat evaluation of Genedrive for U.S. Air Force
The development and evaluation of the Genedrive device, as determined by the agreement, will commence immediately. The agreement is valued at $600,000 over the next five months and was established for the development of software to allow the Genedrive device to readily identify three specific pathogens.
Genedrive is Epistem's handheld molecular pathogen detecting device. If the combat agreement program with the U.S. Air Force is successfully completed, Epistem can secure long-term investments from the U.S. Department of Defense for the continual enhancement of its Genedrive device.
Epistem is also currently preparing to roll out its first Genedrive disease test for the identification of Tuberculosis. The program will launch this year and the company reports it is close to resolving reported issue's with Genedrive's proprietary software and firmware issues.
Epistem will be conducting clinical trials with the Foundation for Innovative New Diagnostics this year, along with attempting to gain Indian regulatory approval. The company is also trying to position itself for a possible recommendation from the World Health Organization in 2015.